Nasus Pharma Announces FDA Clearance to Initiate Clinical Study of NS002 in the Treatment of Anaphylaxis
Nasus Pharma received FDA clearance of its Investigational New Drug application for NS002, an investigational intranasal epinephrine powder positioned as a needle-free alternative to EpiPen for treating anaphylaxis. The pivotal study is planned to start in the fourth quarter of 2026 with topline data anticipated in the first quarter of 2027, and will compare self-administration to administration by a health care professional.
Key figures
- Drug Name
- NS002 (investigational intranasal epinephrine powder)
- Phase Of Trial
- Pivotal study planned for Q4 2026; topline data anticipated Q1 2027
- Market size
- $2 billion
- Prior study
- Phase 2
- Median t100 ns002 minutes
- 1.69
- Median t100 epipen minutes
- 3.47
- Epinephrine plasma threshold pg ml
- 100
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.